Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12589543 | 0.80 | ACE (0.48) | ALDH1A1L3MBTL1KMT2APOLBCYP2D6 | |
| SCHEMBL8593861 | 0.78 | SMN1; SMN2 (0.49) | — | |
| SCHEMBL5758709 | 0.78 | L3MBTL1 (0.51) | ALDH1A1L3MBTL1KMT2AMEN1ACHE | |
| SCHEMBL4120260 | 0.75 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1ACHEPOLB | |
| SCHEMBL6202280 | 0.75 | L3MBTL1 (0.51) | ALDH1A1L3MBTL1KMT2AMEN1ACHE | |
| SCHEMBL5509197 | 0.75 | L3MBTL1 (0.51) | ALDH1A1L3MBTL1KMT2AMEN1ACHE | |
| SCHEMBL16874753 | 0.75 | L3MBTL1 (0.51) | ALDH1A1L3MBTL1KMT2AMEN1ACHE | |
| SCHEMBL14085914 | 0.74 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1KMT2APOLBCYP2D6 | |
| SCHEMBL24200353 | 0.74 | CHRM2 (0.52) | ALDH1A1L3MBTL1KMT2AMEN1ACHE | |
| SCHEMBL6732065 | 0.74 | HSD11B1 (0.55) | ALDH1A1L3MBTL1KMT2AMEN1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | ALDH1A1 824/4885L3MBTL1 2900/4885KMT2A 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.